Kidney Cancer Drugs

Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships

Medical / /

Roots Analysis has announced the addition of the “Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships” report to its list of offerings.   Biosimilars of bevacizumab are currently approved / being developed to treat colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer. Experts believe that a strong biosimilar portfolio […]

Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships Read More »

With over 20 approved products and several under development, the Avastin® biosimilars market is projected to witness noteworthy growth

Health & Fitness / /

In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved   Roots Analysis has announced the addition of the “Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships”

With over 20 approved products and several under development, the Avastin® biosimilars market is projected to witness noteworthy growth Read More »